Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists

Current Cardiology Reports

Volumn 13, Issue 5, 2011, Pages 439-450

  De Labriolle, Axel ^a   Doazan, Jean Philippe ^b   Lemesle, Gilles ^c   Bonello, Laurent ^d  

^a Clinique du Pont de Chaume   (France)

^b Centre Hospitalier de Montauban   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HÔPITAL NORD   (France)

Author keywords

Acute coronary syndrome; Adenosine diphosphate; Antiplatelet therapy; Individualized therapy; P2Y12 ADP receptor; Pharmacogenomics; Platelet reactivity; Stent thrombosis

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; PLACEBO; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; R 138727; TICAGRELOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CYP2C19 GENE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; THROMBOCYTE FUNCTION;

ADENOSINE; CORONARY ARTERY DISEASE; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 81255136229     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-011-0208-z     Document Type: Article

References (68)

1. Lange RA, Hillis LD. Antiplatelet therapy for ischemic heart disease. N Engl J Med. 2004;350:277-80. (Pubitemid 38067641)
2. Dorsam RT, Kunapuli SP Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113:340-5. (Pubitemid 38544175)
3. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol. 2006;46:277-300. (Pubitemid 43271191)
4. Patrono C, Baigent C, Hirsh J, et al. American College of Chest Physicians, Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:199S-233S. (Pubitemid 351894914)
5. Kushner FG, Hand M, Smith Jr SC, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205-41.
6. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-13. (Pubitemid 36736631)
7. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822-34. (Pubitemid 350007957)
8. Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005;45:1392-6. (Pubitemid 40615608)
9. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J. 2004;25:1903-10. (Pubitemid 39452607)
10. Gurbel PA, Tantry US. Drug insight: clopidogrel nonresponsive-ness. Nat Clin Pract Cardiovasc Med. 2006;3:387-95.
11. Wiviott SD, Braunwald E, McCabe CH; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med 2007, 357: 2001-2015. (Pubitemid 350106708)
12. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2010;361:1045-57
13. TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009;30:1753-63.
14. Hagihara K, Kazui M, Kurihara A, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos. 2009;37:2145-52.
15. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-9.
16. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30:1288-95. (Pubitemid 35265838)
17. Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA. 2003;103:11069-74. (Pubitemid 44148419)
18. Price MJ, Coleman JL, Steinbhul SR, et al. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006;98:681-4. (Pubitemid 44233472)
19. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSETof the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSETstudy. Circulation. 2009;120:2577-85.
20. Easthope SE, Jarvis B. Clopidogrel: potential in the prevention of cardiovascular events in patients with acute coronary syndromes. Am J Cardiovasc Drugs. 2001;1:467-74.
21. Niitsu Y, Sugidachi A, Ogawa T, et al. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity. in several animal species. Eur J Pharmacol. 2008;579:276-82.
22. Sugidachi A, Asai F, Yoneda K, et al. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Glinked P2T antagonist, CS-747. Br J Pharmacol. 2001;132:47-54. (Pubitemid 32128433)
23. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129:1439-46. (Pubitemid 30175717)
24. Frelinger AL, Jakubowski JA, Li Y, et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007;98:192-200. (Pubitemid 47074196)
25. Jakubowski JA, Payne CD, Brandt JT, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006;47:377-84. (Pubitemid 44309690)
26. Jakubowski JA, Payne CD, Weerakkody GJ, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacology. 2007;49:167-73. (Pubitemid 46579951)
27. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-4. (Pubitemid 40740853)
28. Rehmel JL, Eckstein JA, Farid NA, et al. Interaction of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;34:600-7.
29. Koo MH, Nawarskas JJ, Frishman WH. Prasugrel. A new antiplatelet drug for the prevention and treatment of cardiovascular disease. Cardiol Rev. 2008;16:314-8.
30. Ernest CS, Small DS, Rohatagi S, et al. Population pharmacoki-netics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. J Pharmacokinet Pharmacodyn. 2008;35:593-618.
31. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38:1514-21.
32. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolera-bility and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66:487-96.
33. Simon T, Verstuyft C, Mary-Karuse M, et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-75.
34. Collet JP, Silvain J, Landivier A, et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the reload with clopidogrel before coronary angioplasty in subjects treated long term with dual antiplatelet therapy (RELOAD) study. Circulation. 2008;118:1225-33.
35. Gurbel A, Antonino MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol. 2009;5:989-1004.
36. Marín F, González-Conejero R, Capranzano P, et al. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009;54:1041-57.
37. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166-71. (Pubitemid 38114134)
38. Lau WC, Gurbel PA, Carville DG, et al. Saint John's wort enhances clopidogrel responsiveness in clopidogrel resistance volunteers and patients by induction of CYP3A4 isoenzymes [abstract]. J Am Coll Cardiol. 2007;49:343A.
39. Bliden KP, DiChiara J, Lookman L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol. 2008;52:531-3.
40. Berger JS, Bhatt DL, Steinhubl SR, and CHARISMA Investigators. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation. 2009;120:2337-44.
41. Desai NR, Mega JL, Jiang S, et al. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol. 2009;53:1273-8.
42. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-60.
43. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48:475-84. (Pubitemid 351389118)
44. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157:148e1-5.
45. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;10:714-9.
46. Verstuyft C, Simon T, Kim RB. Personalized medicine and antiplatelet therapy: ready for prime time? Eur Heart J. 2009;30:1943-63.
47. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849-57.
48. US Food and Drug Administration. FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed March 24, 2010.
49. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681GA polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925-34. (Pubitemid 351636443)
50. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-62.
51. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373:309-317.
52. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916-22.
53. Bhatt DL, Simonsen KL, Emison ES, et al., on behalf of the CHARISMA Executive Committee and Investigators. CHARISMA genomics. Paper presented at Transcatheter Cardiovascular Therapeutics 2009 Meeting; September 30, 2009; San Francisco, California.
54. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119:2553-60.
55. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320-8.
56. Bonello L, Tantry US, Marcucci R. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-33.
57. Mokhtar OA, Lemesle G, Armero S, et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res. 2010;126(2):e147-9.
58. Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? Euro-Intervention. 2009;5(3):325.
59. Bonello L, Armero S, Armero O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol. 2010;56:1630-6.
60. Collet JP, Hulot JS, Anzaha G, CLOVIS-2 Investigators. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv. 2011;4:392-402.
61. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51 (14):1404-11. (Pubitemid 351447314)
62. Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-105.
63. Bonello L, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary interventions in acute coronary syndromes. J Am Coll Cardiol 2011 (in press).
64. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774-82. (Pubitemid 44268228)
65. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430-5. (Pubitemid 41134272)
66. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol. 2004;16:169-74. (Pubitemid 38456448)
67. Sibbing D, von Beckerath O, Schömig A, et al. Platelet function in clopidogrel-treated patients with acute coronary syndrome. Blood Coagul Fibrinolysis. 2007;18:335-9. (Pubitemid 46699410)
68. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55:2427-34.